Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist

Area of Science:

• Neuroscience
• Pharmacology
• Endocrinology

Background:

• Estrogen's role in pain perception is complex and debated, with studies reporting both beneficial and detrimental effects.
• Non-selective estrogen administration has yielded conflicting results in animal pain models.

Purpose of the Study:

• To evaluate the efficacy of ERb-131, a selective estrogen receptor beta (ERb) agonist, in preclinical pain models.
• To determine if ERb-131 exhibits estrogen receptor alpha (ERa) activity.

Main Methods:

• ERb-131 was characterized using functional and binding assays for ERb and ERa selectivity.
• In vivo efficacy was tested in animal models of nerve injury and chemical sensitization.
• A rat uterotrophic assay assessed ERa activity.

Main Results:

• ERb-131 demonstrated potent and selective ERb agonism.
• The compound was devoid of ERa activity in the uterotrophic assay.
• ERb-131 alleviated hyperalgesia and allodynia in multiple pain models but did not alter pain thresholds in healthy animals.

Conclusions:

• Selective estrogen receptor beta agonism is a viable strategy for attenuating diverse pain states.
• ERb-131 shows potential as a therapeutic agent for neuropathic and other pain conditions.
• Targeting ERb offers a way to modulate pain without the side effects associated with non-selective estrogen receptor activation.